Business Segments Abbisko Cayman Limited
Equities
2256
KYG0028A1085
Biotechnology & Medical Research
|
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
| 13.33 HKD | -2.49% |
|
+4.14% | +2.46% |
Sales 2024 by Business Segment
Sales 2024 by Geography
Historical Breakdown of Revenue by Business Segments
Net Income: Breakdown by Business Segment
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
Biological Products | ||||||
Development of Innovative Medicines | 7.3M | 22.68M | - | 19.06M | 504M | |
Total Assets | 666M | 2.65B | 2.49B | 2.12B | 2.11B | |
Interest Expense | -338K | -959K | -2.68M | -2.17M | -1.61M | |
Income Tax Expense | - | - | - | - | 49.73M | |
CAPEX | -4.03M | -12.34M | -22.75M | -9.6M | -4.07M | |
EBT | -707M | -1.81B | -496M | -432M | 78.03M | |
Gross Profit | - | 22.68M | - | 19.06M | 504M | |
D&A | 9.49M | 11.89M | 14.12M | 15.76M | 20.44M | |
Net Income | -707M | -1.81B | -496M | -432M | 28.3M |
Geographical Revenue Distribution History
| Fiscal Period: December | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 |
|---|---|---|---|---|---|---|
Mainland China | 7.3M | 22.68M | - | 19.06M | 504M | |
Total Assets | 666M | 2.65B | 2.49B | 2.12B | 2.11B | |
Interest Expense | -338K | -959K | -2.68M | -2.17M | -1.61M | |
Income Tax Expense | - | - | - | - | 49.73M | |
D&A | 9.49M | 11.89M | 14.12M | 15.76M | 20.44M | |
CAPEX | -4.03M | -12.34M | -22.75M | -9.6M | -4.07M | |
Gross Profit | - | 22.68M | - | 19.06M | 504M | |
Net Income | -707M | -1.81B | -496M | -432M | 28.3M | |
EBT | -707M | -1.81B | -496M | -432M | 78.03M |
- Stock Market
- Equities
- 2256 Stock
- Financials Abbisko Cayman Limited
- Business Segments
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition